Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

被引：9

作者：

Boni, V. ^{[1
]}

Drilon, A. ^{[2
]}

Deeken, J. ^{[3
]}

Garralda, E. ^{[4
]}

Chung, H. ^{[5
]}

Kinoshita, I. ^{[6
]}

Oh, D. ^{[7
]}

Patel, J. ^{[8
]}

Xu, R. ^{[9
]}

Norenberg, R. ^{[10
]}

Brega, N. ^{[11
]}

Dima, L. ^{[12
]}

Hong, D. ^{[13
]}

Berlin, J. ^{[14
]}

机构：

[1] HM Hosp Univ Sanchinarro, START Madrid CIOCC, Madrid, Spain

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[3] Inova Fairfax Hosp, Inovar Schar Canc Inst, Fairfax, VA USA

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[6] Hokkaido Univ Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[7] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[8] Northwestern Univ, Chicago, IL 60611 USA

[9] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China

[10] Chrestos Concept GmbH & Co KG, Essen, Germany

[11] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[12] Bayer Consumer Care AG, Basel, Switzerland

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[14] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

来源：

关键词：

D O I：

10.1016/j.annonc.2021.05.053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SO-29

引用

页码：S214 / S215

页数：2